Diabetes and Cholesterol Metabolism

Welcome Message

Welcome to the 10th International Conference on Diabetes and Cholesterol Metabolism, taking place on April 16–17, 2026, in Tokyo, Japan. This conference, themed “Molecular and Clinical Perspectives on Cholesterol Metabolism in Diabetes,” brings together global experts, researchers, and clinicians to explore the latest scientific advances and clinical insights in this important area. The program is designed to encourage meaningful discussions, knowledge exchange, and collaborative efforts that bridge molecular research and patient-centered care. We are confident that this meeting will contribute to a deeper understanding of disease mechanisms and improved therapeutic strategies, while also offering participants the opportunity to experience the vibrant culture and innovation of Tokyo.

About Conference

The 10th International Conference on Diabetes and Cholesterol Metabolism will be held on April 16–17, 2026, in Tokyo, Japan, bringing together researchers, clinicians, and industry experts from around the world. Organized around the theme “Molecular and Clinical Perspectives on Cholesterol Metabolism in Diabetes,” the conference aims to integrate basic molecular research with clinical insights to advance understanding, diagnosis, and treatment of metabolic disorders. The scientific program will include keynote lectures, plenary talks, panel discussions, and poster presentations showcasing the latest research and therapeutic developments. This conference will serve as a dynamic platform for networking, collaboration, and the exchange of innovative ideas, while also offering participants the opportunity to experience Tokyo’s unique blend of tradition, culture, and modern innovation.

Why To Attend ?

The 10th International Conference on Diabetes and Cholesterol Metabolism offers cutting-edge insights into the latest advances in diabetes and lipid metabolism research, prevention, and treatment. It brings together global experts to share evidence-based strategies, clinical innovations, and emerging therapies shaping the future of metabolic healthcare. The conference provides a dynamic platform for networking with researchers, clinicians, industry leaders, and policymakers from across the world. Attendees will benefit from interactive sessions, case-based discussions, and translational research highlights. This event empowers participants to enhance clinical outcomes, build meaningful collaborations, and stay ahead in the rapidly evolving field of metabolic health.

Target Audience:

• Endocrinologists
• Cardiologists
• Diabetologists
• Lipidologists
• Internal Medicine Physicians
• Clinical Researchers 
• Pharmacologists
• Nutritionists and Dietitians
• Public Health Professionals
• Biomedical Scientists
• Medical and Nursing Professionals Vascular Surgeons
• Clinical Trial Coordinators
• Regulatory Affairs Specialists
• Epidemiologists
• Neurologists
• Vascular Surgeons
• Clinical Trial Coordinators
• Regulatory Affairs Specialists

Sessions And Tracks

Track 1: Foundations of Diabetes and Cholesterol Metabolism

Explores the fundamental biological and physiological mechanisms underlying glucose and lipid metabolism. This session provides an overview of metabolic homeostasis and dysregulation leading to diabetes and cholesterol disorders. It examines hormonal regulation, energy balance, and metabolic pathways. The interaction between genetics and environment is highlighted. This track establishes a strong scientific foundation for advanced clinical and translational discussions.                                                                                                                          

Focus Areas:

• Basic Metabolic Pathways in Glucose and Lipid Regulation
• Hormonal Control of Metabolism
• Metabolic Homeostasis and Dysregulation

Track 2: Epidemiology and Global Burden of Metabolic Disorders

Focuses on the worldwide prevalence and rising incidence of diabetes and dyslipidemia. The session examines demographic, socioeconomic, and geographic trends. Risk factors including lifestyle, urbanization, and aging populations are discussed. Data-driven insights into disease burden and healthcare impact are emphasized. Strategies for population-level surveillance are explored.

Focus Areas:

• Global and Regional Disease Trends
• Risk Factor Analysis and Population Studies
• Public Health Surveillance Models

Track 3: Genetics and Molecular Basis of Diabetes

Examines genetic susceptibility and molecular mechanisms contributing to diabetes. The session discusses gene–environment interactions and epigenetic influences. Advances in genomics and molecular diagnostics are highlighted. Translational implications for risk prediction and early diagnosis are explored. Emerging therapeutic targets are reviewed.

Research Focus:

• Genetic Risk Factors and Polymorphisms
• Epigenetics and Metabolic Regulation
• Molecular Targets in Diabetes

Track 4: Pathophysiology of Insulin Resistance

Explores cellular and systemic mechanisms leading to insulin resistance. The session discusses inflammation, oxidative stress, and mitochondrial dysfunction. Tissue-specific insulin resistance in liver, muscle, and adipose tissue is examined. Links to obesity and metabolic syndrome are emphasized. Clinical implications for disease progression are highlighted.

Scientific Insights:

• Cellular Mechanisms of Insulin Resistance
• Role of Inflammation and Oxidative Stress
• Tissue-Specific Metabolic Dysfunction

Track 5: Type 1 Diabetes – Mechanisms and Management

Focuses on autoimmune mechanisms driving Type 1 diabetes. The session examines beta-cell destruction and immune dysregulation. Advances in immunotherapy and disease-modifying strategies are discussed. Clinical management and insulin delivery innovations are highlighted. Long-term outcomes and quality of life considerations are addressed.

Clinical Priorities:

• Autoimmune Pathogenesis of Type 1 Diabetes
• Insulin Therapy and Technological Advances
• Long-Term Management Strategies

Track 6: Type 2 Diabetes – Clinical Management and Therapeutics

Explores comprehensive management strategies for Type 2 diabetes. The session reviews pharmacological and non-pharmacological interventions. Emerging drug classes and combination therapies are discussed. Patient-centered care and individualized treatment plans are emphasized. Outcomes-based approaches are highlighted.

Therapeutic Focus:

• Antidiabetic Drug Therapies
• Lifestyle and Behavioral Interventions
• Personalized Treatment Strategies

Track 7: Prediabetes and Early Intervention Strategies

Addresses early metabolic abnormalities and disease prevention. The session examines diagnostic criteria and biomarkers for prediabetes. Lifestyle modification and risk-reduction strategies are discussed. Community-based prevention programs are highlighted. Opportunities for delaying disease progression are explored.

Preventive Focus:

• Early Detection and Risk Assessment
• Lifestyle-Based Intervention Models
• Population Prevention Strategies

Track 8: Cholesterol Metabolism and Lipid Disorders

Focuses on cholesterol synthesis, transport, and regulation. The session examines dyslipidemia and its metabolic consequences. Genetic and lifestyle influences on lipid profiles are discussed. Diagnostic approaches and lipid biomarkers are highlighted. Therapeutic targets in lipid metabolism are explored.

Key Topics:

• Cholesterol Biosynthesis and Transport
• Dyslipidemia Pathophysiology
• Lipid Biomarkers and Diagnostics

Track 9: Diabetes and Cardiovascular Risk

Examines the strong association between diabetes, cholesterol, and cardiovascular disease. The session discusses atherosclerosis and endothelial dysfunction. Risk stratification and early detection strategies are highlighted. Integrated cardio-metabolic management approaches are explored. Prevention of adverse cardiovascular outcomes is emphasized.

Clinical Focus:

• Atherosclerosis in Diabetes
• Cardio-Metabolic Risk Assessment
• Preventive Cardiology Strategies

Track 10: Lipid-Lowering Therapies and Innovations

Explores current and emerging treatments for cholesterol management. The session discusses statins, PCSK9 inhibitors, and novel agents. Combination therapies and treatment optimization are reviewed. Safety and long-term efficacy are emphasized. Future therapeutic pipelines are highlighted.

Therapeutic Highlights:

• Pharmacological Lipid Management
• Emerging Lipid-Lowering Agents
• Safety and Efficacy Considerations

Track 11: Obesity and Metabolic Syndrome

Examines obesity as a central driver of metabolic disorders. The session explores adipose tissue biology and inflammation. Links between obesity, diabetes, and dyslipidemia are discussed. Prevention and management strategies are highlighted. Multidisciplinary care approaches are emphasized.

Metabolic Focus:

• Obesity-Driven Metabolic Dysfunction
• Adipose Tissue and Inflammation
• Integrated Management Models

Track 12: Nutrition, Diet, and Metabolic Health

Focuses on dietary patterns influencing glucose and lipid metabolism. The session examines macronutrients, micronutrients, and dietary interventions. Evidence-based nutritional strategies are discussed. Cultural and regional dietary considerations are highlighted. Personalized nutrition approaches are explored.

Nutritional Insights:

• Diet and Glycemic Control
• Nutritional Strategies for Lipid Management
• Personalized and Cultural Nutrition

Track 13: Physical Activity and Lifestyle Interventions

Explores the role of physical activity in metabolic health. The session examines exercise physiology and insulin sensitivity. Behavioral strategies for sustained lifestyle change are discussed. Technology-assisted lifestyle interventions are highlighted. Long-term health benefits are emphasized.

Lifestyle Strategies:

• Exercise and Metabolic Regulation
• Behavioral Change Models
• Technology-Supported Interventions

Track 14: Diabetes-Related Complications

Examines microvascular and macrovascular complications of diabetes. The session discusses neuropathy, nephropathy, and retinopathy. Early detection and management strategies are emphasized. Multisystem impacts are highlighted. Improving patient outcomes remains central.

Clinical Concerns:

• Microvascular Complications
• Multisystem Disease Progression
• Preventive and Therapeutic Strategies

Track 15: Diabetic Kidney Disease

Focuses on renal complications associated with diabetes.The session explores pathophysiology and disease progression. Biomarkers and early diagnostic tools are discussed. Renoprotective therapies are highlighted. Integrated care approaches are emphasized.

Renal Focus:

• Pathogenesis of Diabetic Nephropathy
• Early Diagnosis and Biomarkers
• Renal Protection Strategies

Track 16: Digital Health and Diabetes Technology

Explores technological innovations transforming diabetes care. The session discusses continuous glucose monitoring and insulin pumps. AI-driven decision support systems are highlighted. Telemedicine and remote monitoring models are examined. Data integration and patient engagement are emphasized.

Technology Highlights:

• Diabetes Monitoring Technologies
• AI and Digital Decision Support
• Telehealth and Remote Care

Track 17: Precision and Personalized Medicine

Examines individualized approaches to diabetes and cholesterol management. The session discusses genomics, biomarkers, and risk profiling. Tailored therapeutic strategies are explored. Digital and diagnostic tools supporting precision care are highlighted. Future directions are examined.

Personalization Elements:

• Biomarker-Guided Therapies
• Precision Risk Stratification
• Individualized Treatment Models

Track 18: Public Health Policy and Prevention

Focuses on policy-driven approaches to metabolic disease prevention. The session examines healthcare systems and economic impact. National and global prevention strategies are discussed. Community engagement and health equity are emphasized. Policy innovation is highlighted.

Policy Focus:

• Public Health Strategies
• Health Economics and Policy Impact
• Community and Equity-Based Prevention

Track 19: Clinical Trials and Translational Research

Explores clinical research advancing diabetes and cholesterol care. The session discusses trial design and regulatory considerations. Translating basic science into clinical practice is emphasized. Ethical and methodological challenges are addressed. Collaborative research models are highlighted.

Research Focus:

• Clinical Trial Methodology
• Translational Medicine Approaches
• Ethics and Regulatory Compliance

Track 20: Future Directions in Diabetes and Cholesterol Research

Explores emerging trends shaping the future of metabolic healthcare. The session discusses novel therapies and interdisciplinary collaboration. Integration with global healthcare systems is examined. Challenges and opportunities are identified. A strategic vision for the next decade is presented.

Forward Outlook:

• Emerging Therapies and Innovations
• Global Collaboration in Metabolic Research
• Sustainable and Future-Focused Care

Market Analysis

The diabetes and cholesterol metabolism market is expanding rapidly, driven by the rising global prevalence of type 2 diabetes, obesity, and dyslipidemia. Growing awareness of cardiometabolic risks and increased screening are propelling demand for advanced diagnostics and monitoring solutions. Innovative pharmacological treatments such as GLP-1 receptor agonists, SGLT2 inhibitors, statins, and PCSK9 inhibitors—are capturing significant market share and improving patient outcomes. Additionally, integration of digital health tools and personalized care approaches is enhancing long-term disease management. Emerging markets with improving healthcare infrastructure are further contributing to overall growth.

GLP-1–Based Therapies in Diabetes & Metabolic Health :

GLP-1–based therapies represent the most transformative advancement in diabetes and metabolic disease management. These agents not only improve glycemic control but also promote significant weight loss and reduce cardiovascular risk, making them central to comprehensive metabolic care. Rapidly expanding indications now include obesity, heart failure, and chronic kidney disease, broadening their clinical and commercial impact. Strong real-world outcomes, high patient demand, and premium pricing models continue to drive market growth. With robust pipelines and ongoing innovation, GLP-1 therapies are redefining the future of diabetes and cardiometabolic treatment.       

Dyslipidemia & Novel Cholesterol-Lowering Therapies (PCSK9 & Beyond) :

Dyslipidemia remains a major contributor to cardiovascular disease, driving sustained demand for effective lipid-lowering treatments. While statins remain foundational, unmet needs due to intolerance and suboptimal LDL control have accelerated adoption of novel therapies. PCSK9 inhibitors and emerging oral agents offer potent LDL-cholesterol reduction with improved clinical outcomes. Advances in combination therapies and personalized lipid management are further expanding treatment options. Ongoing innovation beyond PCSK9 is reshaping long-term cardiovascular risk reduction and market growth.

Past Conference

The 9th International Conference on Diabetes and Cholesterol Metabolism, held in Tokyo, Japan from April 16 to April 17, 2025, successfully brought together leading endocrinologists, cardiologists, researchers, and healthcare professionals from around the world. The conference featured high-impact keynote lectures, scientific sessions, and interactive discussions focused on recent advances in diabetes management and lipid metabolism. Participants gained valuable evidence-based insights that supported improved clinical practice and translational research. The event also promoted interdisciplinary collaboration through workshops and poster presentations. Overall, the 9th edition played a significant role in strengthening global partnerships and advancing innovation in metabolic health.

Benefits Of Participation

Benefits of Participation- Speaker

• Worldwide acknowledgment of Researcher’s profile
• Make Lasting connections at Networking and Social Events
• An opportunity to give One-page advertisement in abstract book and flyers distribution which eventually gets 1 Million views and add great value to your research profile
• Learn beyond your field of interest, a change to know more about the new topics and research apart from your core subject from METABOLIC DISEASES.
• We provide unique convergence of Networking, Learning and Fun into a single package

Benefits of Participation- Delegate

• Professional Development –Uplift the knowledge and skills
• Attendance inspires, rejuvenates, and energizes delegates
• Your participation at our conference will be helpful for a new approach and ideology that can be utilized for the extending the outcome of companies or industries.
• Opportunities to meet through online webinar for METABOLIC DISEASES 2026 researchers and experts of same field and share new ideas.

Benefit of Participation- Sponsor

• Exposure to the international atmosphere will increase the odds of getting new business
• Opportunity to showcase the new technology, new products of your company, or the service your industry to a broad international participant.
• World’s No. 1 platform to show case products.
• Increase business by lead generation through our conference participants.
• METABOLIC DISEASES 2026 conferences create opportunities for greater focus and reflection that could help you take your business to the next level.
• Benchmarking key strategies for business and moving it forward
• Real Benefits in New business-Many Organizations make deals and sign contracts at our METABOLIC DISEASES 2026.

Benefit of Association for Collaborators

• No one in the world have this huge visitor towards METABOLIC DISEASES 2026 , this is the best platform to showcase the society create long-lasting relationships with the peers

• Promotional content and Logo of your Association at our conference banner, website and other proceedings, branding and marketing material will increase your subscribers/Members number by 40%.
• Our event visibility to your Organization page can give a great impact for your association in the Global Market forum.
• Your representatives can network with key conference delegates to update their knowledge and understanding of your organization and services.
• Details will be incorporated with METABOLIC DISEASES 2026 promotional materials like flyers, brochure, pamphlets, program which will be distributed to Hospitals, Universities, Society and Researchers.

Visa Trip Advisor

Planning a trip to Tokyo, Japan? Attend our Meeting!

Issue with VISA?

To support participants in their Visa Application Process, we provide VISA support documents as follows:

1. Official Letter of Invitation
2. Official Letter of Abstract Acceptance
3. Receipt of Payment

Points to note:

• Visa Letter (official letter of invitation) will be issued only after successful registration and payment for the conference.
• Visa Letters can be issued only for the individual accepted to attend the conference.
• Please contact the Program Manager – meevents@memeetings.com to arrange for a Visa Letter.

Kindly provide us with the following information for Visa Letters:

• Your name as it appears on your passport
• Passport Scan Copy (passport number and date of birth)
• Abstract Acceptance letter

Payment Methods:

1. Payment Gateway –
2.  Bank-to-Bank transfer

Having trouble with registration?

Please contact Program Manager – meevents@memeetings.com METABOLIC DISEASES 2026, team will provide you with an INVOICE for the requested price, enabling you to make the Bank-to-Bank transfer.